Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05525481
Other study ID # NL81896.078.22
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date November 1, 2022
Est. completion date February 28, 2024

Study information

Verified date October 2023
Source Erasmus Medical Center
Contact Ruben van Nijnatten
Phone 0683995382
Email r.vannijnatten@erasmusmc.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Adjuvant treatment with tamoxifen is the standard of care for women with estrogen receptor positive (ER+) breast cancer. Tamoxifen is converted to endoxifen, its active metabolite, via CYP2D6 enzymes. The literature states that an endoxifen concentration of at least 16 nmol/L is needed to produce a therapeutic effect (4). Therapeutic Drug Monitoring (TDM) has been proven to be a successful technique to reach the 16 nmol/L endoxifen threshold after 6 months. However, in general TDM can only be used when a drug is in steady-state, which for endoxifen is reached after 3 months for normal metabolizers. For poor- and intermediate metabolizers, the time until steady-state is presumably even longer. This could possibly result in undertreatment within the first 3 to 6 months of tamoxifen treatment. In this study, model-informed precision dosing (MIPD) will be used to counter this problem. The Pharmacokinetic-model, which is used for MIPD, includes CYP2D6 genotype, co-medication, age, body height, BMI and CYP2D6/CYP3A inhibitor use to predict a patient tailored dose. Using MIPD, our aim is to decrease the proportion of patients that are undertreated within the first three months of tamoxifen treatment.


Description:

Tamoxifen, a selective estrogen receptor modulator, is currently the standard-of-care adjuvant treatment of breast cancer. Tamoxifen is a prodrug and particularly exerts its effect through its most active metabolite endoxifen. Cytochrome P450 (CYP) enzymes, in particular CYP2D6, convert tamoxifen to endoxifen. Polymorphisms in the CYP2D6 gene can hamper CYP2D6 activity and subsequently lead to decreased concentrations of endoxifen. Madlensky et al. found a direct association between endoxifen concentrations and breast cancer recurrence in a retrospective cohort. Patients with endoxifen concentrations below 16 nmol/L had a 30% higher risk of breast cancer recurrence than patients with endoxifen concentrations above this threshold. Madlensky et al. also found that CYP2D6 intermediate- and poor metabolizer phenotypes were associated with endoxifen levels below the 16 nmol/L threshold. The association between CYP2D6 phenotypes and endoxifen levels has since been confirmed by several other studies. In several retrospective studies, approximately 20-24% of tamoxifen patients do not reach the 16 nmol/L endoxifen threshold at steady state. Therapeutic drug monitoring (TDM) could be used to increase the probability of reaching this threshold to 89% after 6 months. With TDM, the dose is corrected after reaching steady state and patients are often only adequately treated after 3 to 6 months. To counter this problem and predict the correct tamoxifen dose at baseline, model-informed precision dosing (MIPD) could be used. In prior research at the Erasmus MC a population-pharmacokinetic (POP-PK) model has been developed. POP-PK-modeling is a mathematical modeling technique that describes the pharmacokinetics of a drug for each individual based on patient characteristics. A POPPK model can describe and predict the absorption, distribution, metabolism and elimination of a drug in the body and predict blood concentration-time profiles prior to actual administration of the drug. In previous, not yet published research we have developed a POP-PK model to describe tamoxifen and endoxifen pharmacokinetics. In this model we have evaluated the activity of different single nucleotide polymorphisms (SNP's) on a continuous scale. In addition the concomitant administration of CYP3A4 and CYP2D6 inhibitors influenced endoxifen formation. Whereas age significantly influenced tamoxifen clearance, BMI and height affected the endoxifen formation rate and tamoxifen clearance respectively. After careful retrospective validation the validity of our model can be tested by prospectively predicting the best dose for each patient. Using Monte-Carlo simulations we estimated that when using the standard dose of 20 mg tamoxifen, 23% of all patients will not reach endoxifen steady-state concentration >16 nM. Using model-informed precision dosing, the proportion of patients that reach steady-state endoxifen concentrations above 16 nmol/L will be 91%. Out of these final 9%, 66% of all patients will not reach 16 nM using the highest registered dose of 40 mg. If the POP-PK model could adequately identify this patient group, that will not reach the 16 nM threshold with the highest prescribed dose of 40 mg, they could in the future be treated differently from the start of adjuvant therapy. An example of this are aromatase inhibitors. The primary aim of this study is to increase the proportion of patients that reach an endoxifen level of 16 nM after reaching steady state endoxifen plasma concentrations using MIPD. In this study we will be prospectively validating a POP-PK model and evaluate the feasibility of MIPD for routine clinical use.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date February 28, 2024
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age = 18 years; 2. WHO Performance Status = 1 (see Appendix A); 3. Patients with primary breast cancer, with a prescription for adjuvant tamoxifen treatment; 4. Willing to abstain from strong and moderate CYP3A4 or CYP2D6 inhibitors or inducers, according to: CYTOCHROME P450 DRUG INTERACTION TABLE - Drug Interactions (iu.edu); 5. Able and willing to sign the Informed Consent Form; 6. Able and willing to undergo blood sampling for PK analysis. Exclusion Criteria: 1. Patients with known alcoholism, drug addiction and/or psychiatric or physiological condition which in the opinion of the investigator would impair treatment compliance; 2. > 2 weeks of tamoxifen treatment before inclusion; 3. Patients who's endoxifen levels have been used for therapeutic drug monitoring in the past.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tamoxifen
Hormone therapy

Locations

Country Name City State
Netherlands Erasmus MC Rotterdam Zuid-Holland

Sponsors (1)

Lead Sponsor Collaborator
Erasmus Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary endpoint The primary endpoint is the proportion of patients who reach an endoxifen level of 16 nmol/L or higher. Begin-end (3 months)
Secondary Secondary outcome 1 The total success rate (> 16 nmol/L and < 32 nmol/L) of the POP-PK model as well as in different groups, stratified by dosage as predicted by the POP-PK model. Begin-end (3 months)
Secondary Secondary outcome 2 The predictive value of the POP-PK model for patients who do not reach the 16 nmol/L endoxifen threshold with the highest prescribed tamoxifen dose of 40 mg. Begin-end (3 months)
Secondary Secondary outcome 3 The correlation between the endoxifen values from an early blood sample (4-6 weeks after start of treatment) and the steady-state concentration of endoxifen. Begin-end (3 months)
Secondary Secondary outcome 4 The difference in incidence of side-effects and quality of life between baseline and 3 months after tamoxifen treatment as determined by FACT-ES questionnaires. Begin-end (3 months)
See also
  Status Clinical Trial Phase
Recruiting NCT05534438 - A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer Phase 2
Completed NCT04312347 - Tamoxifen Dose Adjustment on Indonesian Female ER+ Breast Cancer Patients Based on CYP2D6 Genotype and Endoxifen Levels N/A
Recruiting NCT06064812 - A Phase I Clinical Trial of FWD1802 in Patients With ER+/HER2- BC. Phase 1
Completed NCT05423730 - Alcohol and Breast Cancer (ABC) Trial Early Phase 1
Active, not recruiting NCT03983954 - Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors Phase 1
Completed NCT00828854 - Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing Phase 2
Recruiting NCT04824014 - 4FMFES-PET Imaging of ER+ Advanced Breast Cancers Phase 2
Recruiting NCT06395519 - A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies Phase 1
Recruiting NCT04985266 - A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer Phase 2
Completed NCT00676663 - Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer Phase 2
Active, not recruiting NCT04551495 - Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE) Phase 2
Recruiting NCT04920708 - Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression Phase 2
Not yet recruiting NCT06407401 - Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Women With Early Breast Cancer Phase 3
Completed NCT01202591 - Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients Phase 1/Phase 2
Recruiting NCT05490472 - JAB-2485 Activity in Adult Patients With Advanced Solid Tumors Phase 1/Phase 2
Completed NCT02580448 - CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) Phase 1/Phase 2
Recruiting NCT04360941 - PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer Phase 1